CD8A and infection: The significant induction of lung‐resident CD8+ TRM cells by the T4‐CoV‐Flu vaccine is particularly promising, as these cells can provide immediate protection against respiratory viruses at the site of infection, even in the absence of circulating antibodies.[63]